Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Change in Accured Expenses (2020 - 2023)

Cullinan Therapeutics has reported Change in Accured Expenses over the past 4 years, most recently at $5.1 million for Q4 2023.

  • Quarterly results put Change in Accured Expenses at $5.1 million for Q4 2023, up 219.77% from a year ago — trailing twelve months through Dec 2023 was $10.1 million (up 17.82% YoY), and the annual figure for FY2025 was $8.0 million, up 177.24%.
  • Change in Accured Expenses for Q4 2023 was $5.1 million at Cullinan Therapeutics, down from $5.2 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for CGEM hit a ceiling of $5.2 million in Q3 2023 and a floor of -$2.8 million in Q2 2023.
  • Median Change in Accured Expenses over the past 4 years was $1.6 million (2021), compared with a mean of $1.6 million.
  • Peak annual rise in Change in Accured Expenses hit 13304.76% in 2021, while the deepest fall reached 645.12% in 2021.
  • Cullinan Therapeutics' Change in Accured Expenses stood at -$21000.0 in 2020, then soared by 13304.76% to $2.8 million in 2021, then plummeted by 42.91% to $1.6 million in 2022, then surged by 219.77% to $5.1 million in 2023.
  • The last three reported values for Change in Accured Expenses were $5.1 million (Q4 2023), $5.2 million (Q3 2023), and -$2.8 million (Q2 2023) per Business Quant data.